Evidence map›Paper›PMID 36101425›Full record

ArticleBiology2022

Epithelial-Mesenchymal Plasticity Induced by Discontinuous Exposure to TGFβ1 Promotes Tumour Growth.

Mafalda Santos, Marta Ferreira, Patrícia Oliveira, Nuno Mendes, Ana André, André F Vieira, Joana B Nunes, Joana Carvalho, Sara Rocha, Mafalda Azevedo and 12 more

Open access · goldAbstract read
In one paragraph

Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 2 countries.

Mafalda SantosI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
Marta FerreiraI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-3680-8613
Patrícia OliveiraI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
Nuno MendesI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-0570-2277
Ana AndréI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
André F VieiraI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
Joana B NunesI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
Joana CarvalhoI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0001-9743-438X
Sara RochaI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-5390-3807
Mafalda AzevedoIpatimup, Instituto de Patologia e Imunologia Molecular da Universidade do Porto, 4200-465 Porto, Portugal.
Daniel FerreiraI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-9712-1460
Inês ReisIpatimup, Instituto de Patologia e Imunologia Molecular da Universidade do Porto, 4200-465 Porto, Portugal.
João VinagreI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-0871-1427
Joana ParedesI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-1076-1343
Alireza Heravi-MoussaviBritish Columbia Cancer Agency, Vancouver, BC V5Z4E6, Canada.
Jorge LimaI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.
Valdemar MáximoI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-8631-8356
Angela BurleighBritish Columbia Cancer Agency, Vancouver, BC V5Z4E6, Canada.
Calvin RoskelleyBritish Columbia Cancer Agency, Vancouver, BC V5Z4E6, Canada.
Fátima CarneiroI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0002-1964-1006
David HuntsmanBritish Columbia Cancer Agency, Vancouver, BC V5Z4E6, Canada.
Carla OliveiraI3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal.ORCID 0000-0001-8340-2264
Universidade do Porto · PTBC Cancer Agency · CA

Funding

ERDF-NORTE2020-Portugal 2020 NORTE-01-0145-FEDER-000029ERDF-POCI POCI-01-0145-FEDER-007274ERDF-QREN NORTE-07-0162-FEDER-000118ERDF_QREN NORTE-07-0162-FEDER-000067Fundação para a Ciência e Tecnologia FCOMP-01-0124-FEDER-015779Fundação para a Ciência e Tecnologia PD/BD/105976/2014Fundação para a Ciência e Tecnologia PD/BI/113971/2015Fundação para a Ciência e Tecnologia SFRH/BD/81940/2011Fundação para a Ciência e Tecnologia SFRH/BD/90124/2012Fundação para a Ciência e Tecnologia SFRH/BPD/86543/2012Fundação para a Ciência e Tecnologia SFRH/BPD/89764/2012Fundação para a Ciência e Tecnologia SFRH/BPD/90303/2012
6 · The paper itself

Abstract

Transitions between epithelial and mesenchymal cellular states (EMT/MET) contribute to cancer progression. We hypothesize that EMT followed by MET promotes cell population heterogeneity, favouring tumour growth. We developed an EMT model by on and off exposure of epithelial EpH4 cells (E-cells) to TGFβ1 that mimics phenotypic EMT (M-cells) and MET. We aimed at understanding whether phenotypic MET is accompanied by molecular and functional reversion back to epithelia by using RNA sequencing, immunofluorescence (IF), proliferation, wound healing, focus formation and mamosphere formation assays as well as cell xenografts in nude mice. Phenotypic reverted epithelial cells (RE-cells) obtained after MET induction presented epithelial morphologies and proliferation rates resembling E cells. However, the RE transcriptomic profile and IF staining of epithelial and mesenchymal markers revealed a uniquely heterogeneous mixture of cell subpopulations with a high self-renewal ability. RE cell heterogeneity was stably maintained for long periods after TGFβ1 removal both in vitro and in large tumours derived from the nude mice. Overall, we show that phenotypic reverted epithelial cells (RE cells) do not return to the molecular and functional epithelial state and present mesenchymal features related to aggressiveness and cellular heterogeneity that favour tumour growth in vivo. This work strengthens epithelial cell reprogramming and cellular heterogeneity fostered by inflammatory cues as a tumour growth-promoting factor in vivo.

Indexed as

cellular heterogeneityEMTMETself-Renewaltumourigenic potential

Identifiers

PMID36101425
PMCPMC9312510
OpenAlexW4285091802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.